NCT02695940 is a Phase 2 clinical trial of LEO 124249 ointment 30 mg/g in Inverse Psoriasis, sponsored by LEO Pharma.

Who is sponsoring NCT02695940?

NCT02695940 is sponsored by LEO Pharma.

What drugs are being tested in NCT02695940?

Interventions in NCT02695940: LEO 124249 ointment 30 mg/g, LEO 124249 ointment vehicle.

What condition does NCT02695940 study?

NCT02695940 studies Inverse Psoriasis.

Is NCT02695940 still recruiting?

NCT02695940 is currently completed. Last updated 21 February 2025.

Last reviewed 2025-02-21 · How we verify

NCT02695940

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis

Completed Phase 2 Last updated 21 February 2025

What this trial tests

Phase 2 trial testing LEO 124249 ointment 30 mg/g in Inverse Psoriasis in 69 participants. Completed in 1 September 2016.

Timeline

1 March 2016

Primary endpoint
1 September 2016

1 September 2016

Quick facts

Lead sponsor	LEO Pharma
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	69
Start date	1 March 2016
Primary completion	1 September 2016
Estimated completion	1 September 2016
Sites	1 location across Germany

Drugs / interventions tested

LEO 124249 ointment 30 mg/g — full drug profile →
LEO 124249 ointment vehicle — full drug profile →

Conditions studied

Inverse Psoriasis — all drugs for Inverse Psoriasis →

Sponsor

LEO Pharma — full company profile →

Who can join

Adults 18 to 75, any sex, with Inverse Psoriasis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The total sign score (TSS) at Week 6 (Visit 6)
Time frame: after 6 weeks of treatment

Sponsor's own description

This is a phase 2a trial testing twice daily administration of LEO 124249 ointment 30 mg/g in the treatment of mild to moderate inverse psoriasis. Patients will be treated for 6 weeks, and the efficacy and safety will be compared with the treatment of LEO 124249 ointment vehicle.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Topical and Systemic JAK Inhibitors in Dermatology.
Solimani F, Meier K, Ghoreschi K. · · 2019 · cited 199× · PMID 31849996 · DOI 10.3389/fimmu.2019.02847
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies.
Alexander M, Luo Y, Raimondi G, O'Shea JJ, et al · · 2021 · cited 27× · PMID 35056105 · DOI 10.3390/ph15010048
Current and Emerging Therapies Targeting the IL-23/IL-17 Axis in Psoriasis.
Han SJ, Jung GY, Lee GC, Ki DH, et al · · 2026 · PMID 42059024 · DOI 10.4062/biomolther.2026.019

Verify or expand the search:

Other LEO Pharma trials

Trials by the same sponsor.

NCT07335588 — A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus · Phase 3 · not yet recruiting
NCT07013201 — A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to · Phase 2 · recruiting
NCT06444867 — A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 15896 · Phase 1 · completed
NCT06311682 — A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and · Phase 3 · recruiting
NCT05923099 — A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic De · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02695940 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by LEO Pharma
Last refreshed: 21 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02695940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing